Breaking News Instant updates and real-time market news.

CANF

Can-Fite BioPharma

$1.61

0.02 (1.26%)

07:13
08/09/17
08/09
07:13
08/09/17
07:13

Can-Fite BioPharma completes patient enrollment for Phase II Namodenoson study

Can-Fite BioPharma announced that the Phase II liver cancer clinical trial for Namodenoson, a novel compound for the treatment of advanced hepatocellular carcinoma, has successfully enrolled and randomized all 78 patients planned in the clinical trial protocol. The global Phase II study is being conducted in the U.S., Europe and Israel. Patients with advanced HCC, Child Pugh B, are treated twice daily with 25 mg of oral Namodenoson, the dose found to be the most efficacious in Can-Fite's earlier Phase I/II study. The primary endpoint of the Phase II study is Overall Survival. Secondary endpoints include Progression Free Survival, safety, and the relationship between outcomes and A3AR expression. As is standard in this indication, the primary endpoint of OS requires following the entire patient population until the statistically predetermined number of events occur. Can-Fite is following the survival data closely and will perform the survival analysis at the earliest possible opportunity. Can-Fite's prior Phase I/II study of Namodenoson in this indication successfully achieved its primary and secondary endpoints, with a good safety profile. Most of the patients enrolled in the Phase I/II study had failed prior treatment with Nexavar, the only drug currently approved for this indication. Data also showed that Namodenoson has a liver protective effect that is very unique compared to Nexavar and other drugs under development for HCC which have shown to induce hepato-toxicity.

CANF Can-Fite BioPharma
$1.61

0.02 (1.26%)

10/19/16
ROTH
10/19/16
INITIATION
Target $4
ROTH
Buy
Can-Fite BioPharma reinstated with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv resumed coverage of Can-Fite BioPharma with a Buy rating and $4 price target, saying the company's diversified pipeline offers "multiple shots on goal" and is relatively undervalued. The analyst expects that positive data and management execution over the coming 12-24 months could present investible catalysts.
08/29/16
RODM
08/29/16
INITIATION
Target $6
RODM
Buy
Can-Fite BioPharma assumed with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju assumed coverage of Can-Fite BioPharma with a Buy rating and $6 price target.

TODAY'S FREE FLY STORIES

10:25
08/18/17
08/18
10:25
08/18/17
10:25
General news
Treasury Action: yields steadied above lows »

Treasury Action: yields…

10:25
08/18/17
08/18
10:25
08/18/17
10:25
Conference/Events
Cowen Washington strategist holds analyst/industry conference call »

Washington Research Group…

HPE

HP Enterprise

$17.11

-0.19 (-1.10%)

10:20
08/18/17
08/18
10:20
08/18/17
10:20
Options
Repeat option activity in Hewlett Packard Enterprises »

Repeat option activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

10:20
08/18/17
08/18
10:20
08/18/17
10:20
General news
The Michigan sentiment pop to 97.6 »

The Michigan sentiment…

MDU

MDU Resources

$25.82

0.01 (0.04%)

10:18
08/18/17
08/18
10:18
08/18/17
10:18
Syndicate
Breaking Syndicate news story on MDU Resources »

MDU Resources files mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

10:17
08/18/17
08/18
10:17
08/18/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
08/18/17
08/18
10:16
08/18/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSL

Fossil

$7.77

-0.09 (-1.15%)

10:15
08/18/17
08/18
10:15
08/18/17
10:15
Options
Fossil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
08/18/17
08/18
10:15
08/18/17
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

AMTD

TD Ameritrade

$42.44

-0.93 (-2.14%)

10:13
08/18/17
08/18
10:13
08/18/17
10:13
Conference/Events
TD Ameritrade management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

  • 06

    Sep

DE

Deere

$113.40

-10.58 (-8.53%)

10:12
08/18/17
08/18
10:12
08/18/17
10:12
Hot Stocks
Deere says long term global tail winds for agricultural economy in place »

Comments are from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

CTL

CenturyLink

$19.13

-0.25 (-1.29%)

, LVLT

Level 3

$52.64

-0.35 (-0.66%)

10:12
08/18/17
08/18
10:12
08/18/17
10:12
Recommendations
CenturyLink, Level 3 analyst commentary  »

CenturyLink and Level 3…

CTL

CenturyLink

$19.13

-0.25 (-1.29%)

LVLT

Level 3

$52.64

-0.35 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$197.16

-0.832 (-0.42%)

10:11
08/18/17
08/18
10:11
08/18/17
10:11
Hot Stocks
General Dynamics awarded $115.3M contract modification by Navy »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

10:05
08/18/17
08/18
10:05
08/18/17
10:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

IWM

iShares Trust Russell 2000 Index Fund

$134.44

-0.49 (-0.36%)

, RUT

Russell 2000 Index

10:02
08/18/17
08/18
10:02
08/18/17
10:02
Technical Analysis
Technical View: Russell 2000 Index nears key technical levels »

The Russell 2000 (RUT) is…

IWM

iShares Trust Russell 2000 Index Fund

$134.44

-0.49 (-0.36%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:01
08/18/17
08/18
10:01
08/18/17
10:01
General news
Consumer Sentiment Index data reported »

Consumer Sentiment Index…

QQQ

PowerShares QQQ Trust

$141.33

-2.95 (-2.04%)

10:00
08/18/17
08/18
10:00
08/18/17
10:00
Options
Defensive spread in PowerShares QQQ »

Defensive spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:00
08/18/17
08/18
10:00
08/18/17
10:00
General news
Breaking General news story  »

Dallas Federal Reserve…

IMUC

ImmunoCellular

$0.32

-0.0191 (-5.65%)

09:56
08/18/17
08/18
09:56
08/18/17
09:56
Conference/Events
ImmunoCellular to host conference call »

Business News Update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

ROST

Ross Stores

$53.33

-1.04 (-1.91%)

, EL

Estee Lauder

$102.49

4.165 (4.24%)

09:55
08/18/17
08/18
09:55
08/18/17
09:55
Options
Early notable gainers among liquid option names on August 18th »

Notable gainers among…

ROST

Ross Stores

$53.33

-1.04 (-1.91%)

EL

Estee Lauder

$102.49

4.165 (4.24%)

NEM

Newmont Mining

$37.16

1.11 (3.08%)

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

XEC

Cimarex Energy

$96.89

0.59 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Aug

  • 23

    Aug

DAL

Delta Air Lines

$47.54

0.01 (0.02%)

09:54
08/18/17
08/18
09:54
08/18/17
09:54
Upgrade
Delta Air Lines rating change  »

Follow-up: Delta Air…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$53.41

0.26 (0.49%)

09:54
08/18/17
08/18
09:54
08/18/17
09:54
Upgrade
Southwest rating change  »

Follow-up: Southwest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWN

Southwestern Energy

09:50
08/18/17
08/18
09:50
08/18/17
09:50
Options
Opening action in Southwest Energy expiring puts »

Opening action in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 05

    Sep

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

09:47
08/18/17
08/18
09:47
08/18/17
09:47
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

MATX

Matson

$24.27

-5.08 (-17.31%)

09:46
08/18/17
08/18
09:46
08/18/17
09:46
Downgrade
Matson rating change  »

Matson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.